J. Cosme

发表

Crystal structure of human cytochrome P450 2C9 with bound warfarin

Jose Cosme, H. Jhoti, Harren Jhoti, 2003, Nature.

Photosensitizer and anticancer drug-loaded 2D nanosheet: Preparation, stability and anticancer property

Hongmei Qin, N. Komatsu, S. Shi, 2019, 2D Materials.

Crystal Structures of Human Cytochrome P450 3A4 Bound to Metyrapone and Progesterone

Jose Cosme, Clemens Vonrhein, C. Vonrhein, 2004, Science.

Activity and specificity of a mouse monoclonal antibody to ferric aerobactin

D. Le Roy, A. Andremont, D. Expert, 1992, Infection and immunity.

[Computer model of 3D structure of cytochrome P450 2B4].

Vladlen S. Skvortsov, D. McRee, A. Archakov, 2002, Voprosy meditsinskoi khimii.

Discovery of (2,4-dihydroxy-5-isopropylphenyl)-[5-(4-methylpiperazin-1-ylmethyl)-1,3-dihydroisoindol-2-yl]methanone (AT13387), a novel inhibitor of the molecular chaperone Hsp90 by fragment based drug design.

Gianni Chessari, Brent Graham, Jose Cosme, 2010, Journal of medicinal chemistry.

Microsomal cytochrome P450 2C5: comparison to microbial P450s and unique features.

D E McRee, D. McRee, P. Williams, 2000, Journal of inorganic biochemistry.

Oxidative metabolism of lansoprazole by human liver cytochromes P450.

C. Bonfils, F. Guengerich, P. Maurel, 1995, Molecular pharmacology.

Mammalian microsomal cytochrome P450 monooxygenase: structural adaptations for membrane binding and functional diversity.

D E McRee, D. McRee, P. Williams, 2000, Molecular cell.

Engineering Microsomal Cytochrome P450 2C5 to Be a Soluble, Monomeric Enzyme

Eric F. Johnson, J. Cosme, 2000, The Journal of Biological Chemistry.

Heterologous expression of human drug-metabolizing enzymes.

M. Manns, R. Tukey, C. Strassburg, 1997, Drug metabolism and disposition: the biological fate of chemicals.

Microsomal P450 2C3 is expressed as a soluble dimer in Escherichia coli following modification of its N-terminus.

T. Richardson, C. Wachenfeldt, C. von Wachenfeldt, 1997, Archives of biochemistry and biophysics.

Structure-function of cytochromes P450 and flavin-containing monooxygenases: implications for drug metabolism.

P. Ortiz de Montellano, J. Halpert, O. Sibbesen, 1998, Drug metabolism and disposition: the biological fate of chemicals.

Antipyrine as a probe for human oxidative drug metabolism: Identification of the cytochrome P450 enzymes catalyzing 4‐hydroxyantipyrine, 3‐hydroxymethylantipyrine, and norantipyrine formation

U. Hofmann, M. Eichelbaum, G. Engel, 1996, Clinical pharmacology and therapeutics.

Cytochromes of the P450 2C subfamily are the major enzymes involved in the O-demethylation of verapamil in humans

P. Beaune, M. Eichelbaum, H. Kroemer, 1995, Naunyn-Schmiedeberg's Archives of Pharmacology.

Potent, Selective Inhibitors of Fibroblast Growth Factor Receptor Define Fibroblast Growth Factor Dependence in Preclinical Cancer Models

C. Murray, V. Berdini, D. Newell, 2011, Molecular Cancer Therapeutics.

Human cytochromes P450 expressed in Escherichia coli: production of specific antibodies.

P. Beaune, I. de Waziers, J. Gautier, 1996, Toxicology.

Contribution of human cytochrome P450 to benzo[a]pyrene and benzo[a]pyrene-7,8-dihydrodiol metabolism, as predicted from heterologous expression in yeast.

P. Beaune, D. Pompon, A. Perret, 1996, Pharmacogenetics.

Analyzing binding of N-terminal truncated, microsomal cytochrome P450s to membranes.

Eric F. Johnson, J. Cosme, 2002, Methods in enzymology.